Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01722877
Other study ID # JS-ISR-001, version 1, Rev 2
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 2012
Est. completion date September 2015

Study information

Verified date February 2020
Source Midwest Cardiovascular Research Foundation
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Several studies have shown that stenting of the femoropopliteal artery in the lower leg leads to improved overall results compared to balloon angioplasty alone. However, scar tissue development can occur within the stent, a process called restenosis. Treatment of these in-stent restenotic lesions has a high procedural success rate but recurrence of scar tissue is frequently seen. Several methods have been proposed to treat in-stent restenosis in the lower leg arteries but mixed results have been noted. In this study we hypothesize that simultaneous tissue excision and aspiration using the JetStream Navitus device (Medrad) can lead to a high rate of acute procedural success with low intraprocedural complications and an acceptable recurrence rate of restenosis at 6-month follow-up.


Description:

Data not available yet.


Recruitment information / eligibility

Status Completed
Enrollment 29
Est. completion date September 2015
Est. primary completion date August 2014
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Subject is 18 years of age or older.

2. Subject presents with clinical evidence of peripheral arterial disease with ISR in the femoropopliteal segment (includes common femoral, superficial femoral and popliteal)

3. Subject presents with a Rutherford Classification of 1-5 and has symptoms of rest limb pain, ulcerations or claudication.

4. Target lesion(s) must be viewed angiographically and have =50% stenosis.

5. The atherectomy wire must be placed entirely across all lesions to be treated with no visible evidence of clear or suspected subintimal/substent wire passage.

6. The main target vessel reference diameter must be at least 5 mm.

7. One patent distal run-off vessel with brisk flow is required.

8. Patient is an acceptable candidate for percutaneous intervention using the Jetstream NAVITUS System in accordance with its labeled instructions for use.

9. Patient has signed approved informed consent.

10. Patient is willing to comply with the follow-up evaluations at specified times.

Exclusion Criteria:

1. Subject is unable to understand the study or has a history of non-compliance with medical advice.

2. Subject is unwilling or unable to sign the Informed Consent Form (ICF).

3. Subject is currently enrolled in another clinical investigational study that might clinically interfere with the current study endpoints (e.g., limit use of study-recommended medications, etc.).

4. Subject is pregnant or planning to become pregnant within the study period.

5. Subject has a known sensitivity to contrast media and the sensitivity cannot be adequately pre-medicated for.

6. Subject is diagnosed with chronic renal failure or has a creatinine level > 2.5 mg/dl and is not on chronic dialysis.

7. Subject has a known allergy to heparin, ASA, Plavix.

8. Subject has a history of bleeding disorders or platelet count < 80,000 cells/ml.

9. Subject experiences ongoing cardiac problems (e.g., cardiac arrhythmias, congestive heart failure exacerbation, myocardial infarction, etc.) that, per the investigator, would not make the subject an ideal candidate for study procedures.

10. Subject has a CVA or TIA within 4 weeks prior to JetStream procedure.

11. Subject has an anticipated life span of less than 6 months.

12. Subject is suspected of having an active systemic infection.

13. Subject per the investigator's medical judgment must be excluded from the study.

14. Limited vascular access that precludes safe advancement of the Jetstream NAVITUS System to the target lesion(s).

15. Patient has evidence of intracranial or gastrointestinal bleeding within the past 3 months.

16. Patient has had severe trauma, fracture, major surgery or biopsy of a parenchymal organ within the past 14 days.

17. Patient has any planned surgical intervention or endovascular procedure within 15 days after the index procedure.

18. Use of another debulking device during the index procedure prior to the Jetstream NAVITUS System.

19. Use of another debulking device after the Jetstream NAVITUS system.

-

Study Design


Intervention

Device:
JetStream Navitus
Study to use Jetstream device for use of in-stent restenosis in femoral popliteal artery.

Locations

Country Name City State
United States Trinity Bettendorf Medical Center Bettendorf Iowa
United States VA Medical Center Dallas Texas

Sponsors (2)

Lead Sponsor Collaborator
Midwest Cardiovascular Research Foundation MEDRAD, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Acute Device Success Acute device success is defined as less than or equal to 50% residual stenosis at the index lesion using the JetStream device alone and with no adjunctive balloon angioplasty therapy (via Quantitative Vascular Analysis) and with no serious adverse events. intraprocedural
Primary Acute Procedural Success Acute procedural success is defined as less than or equal to 30 percent residual stenosis (via Quantitative Vascular Analysis) at the index lesion post JestStream atherectomy and final adjunctive treatment And with no serious adverse events. intraprocedural
Secondary Patency Patency is defined as Peak Systolic Velocity Ratio (PSVR) of < 2.4 by duplex criteria. PSVR is obtained by dividing velocity (cm/sec) at the lesion site to the velocity immediately proximal to the lesion. 6 months
Secondary Target Lesion Revascularization Reintervention on the same index lesion at 6 months 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT05335525 - Post-market Clinical Investigation of the Angio-Seal™ VIP VCD (ANGIO-SEAL CLOSE)
Active, not recruiting NCT01903044 - Safety and Efficacy of Autologous Bone Marrow Stem Cells for Lower Extremity Ischemia Treating Phase 1/Phase 2
Completed NCT02228564 - BARD® Study of LIFESTREAM™ Balloon Expandable Covered Stent Treating Iliac Arterial Occlusive Disease N/A
Completed NCT02271529 - Zilver PTX Delivery System N/A
Recruiting NCT02054871 - RCT to Evaluate the Renal Protective Effects of Remote Ischaemic Preconditioning in Peripheral Angioplasty N/A
Completed NCT00822172 - Evaluation of Cilostazol in Combination With L-Carnitine Phase 4
Completed NCT00574782 - Evaluation of the Efficacy of Rosuvastatin in Daily Practice in Untreated High Risk Patients (CHALLENGE) N/A
Completed NCT00029991 - Extract of Ginkgo Biloba (EGB 761) and Vascular Function Phase 1/Phase 2
Completed NCT01355406 - Evaluation of Safety and Efficacy of the FlexStent® Femoropopliteal Self-Expanding Stent System N/A
Recruiting NCT05804097 - Does Increasing Oxygen Nurture Your Symptomatic Ischemic Ulcer Sufficiently? Phase 4
Recruiting NCT03638115 - The VaSecure BTK Study N/A
Active, not recruiting NCT03241459 - Safety and Efficacy of the SurVeil™ Drug-Coated Balloon N/A
Active, not recruiting NCT01661231 - Study to Determine the Performance of the Astron and Pulsar-18 Stents in Europe N/A
Completed NCT01444378 - Absolute Pro® MOMENTUM™ N/A
Completed NCT00753337 - The ACTIVE (Use of the Assurant® Cobalt Iliac Stent System in the Treatment of Iliac Vessel Disease) Study N/A
Completed NCT00538226 - Evaluation of the Effect of the Flowaid Device in Increasing Local Circulation in the Leg Phase 1
Completed NCT00593385 - Atrium iCAST Iliac Stent Pivotal Study N/A
Recruiting NCT00385385 - RESTORE-IT-Study of Rifalazil in Chlamydia Pneumoniae Seropositive Patients With a History of Atherosclerotic Disease Phase 2
Completed NCT00392509 - ALD-301 for Critical Limb Ischemia, Randomized Trial Phase 1/Phase 2
Completed NCT00278603 - Stem Cell Injection for Peripheral Vascular Disease Phase 1